Update on Alzheimer's Disease Therapy and Prevention Strategies

Annual Review of Medicine

Volumn 68, Issue , 2017, Pages 413-430

  Graham, W Vallen ^a   Bonito Oliva, Alessandra ^a   Sakmar, Thomas P ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Division of Neurogeriatrics ^*  (Sweden)

Author keywords

Amyloid; Cognitive impairment; Dementia; Neurodegeneration; Neurofibrillary tangle; Plaque

Indexed keywords

AMYLOID BETA PROTEIN; CHAPERONE; NOOTROPIC AGENT; TAU PROTEIN; AMINO ACID RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; MEMANTINE;

ALZHEIMER DISEASE; BIOCHEMISTRY; CLINICAL TRIAL; DRUG APPROVAL; HUMAN; IMMUNOTHERAPY; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW; AGING; ANIMAL; DRUG EFFECTS; IMMUNOMODULATION; METABOLISM; MICROGLIA; NEUROGENIC INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CHOLINESTERASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; IMMUNOTHERAPY; MEMANTINE; METABOLIC DISEASES; MICROGLIA; MOLECULAR CHAPERONES; NEUROFIBRILLARY TANGLES; NEUROGENIC INFLAMMATION; NEUROIMMUNOMODULATION; TAU PROTEINS;

EID: 85009967873     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-042915-103753     Document Type: Review

References (102)

1. Winblad B, Amouyel P, Andrieu S, et al. 2016. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 15:455-532
2. Winblad B, Poritis N. 1999. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry 14:135-46
3. Pereira AC, Lambert HK, Grossman YS, et al. 2014. Glutamatergic regulation prevents hippocampaldependent age-related cognitive decline through dendritic spine clustering. PNAS 111:18733-38
4. Goate A, Chartier-Harlin MC, Mullan M, et al. 1991. Segregation of a missensemutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-6
5. Sherrington R, Rogaev EI, Liang Y, et al. 1995. Cloning of a gene bearing missense mutations in earlyonset familial Alzheimer's disease. Nature 375:754-60
6. GoateA, Hardy J. 2012. Twenty years of Alzheimer's disease-causing mutations. J. Neurochem. 120(Suppl. 1):3-8
7. Hardy JA, Higgins GA. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-85
8. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-56
9. McCarthy JV, Twomey C, Wujek P. 2009. Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell. Mol. Life Sci. 66:1534-55
10. KopanR, IlaganMX. 2009. The canonical Notch signaling pathway: unfolding the activationmechanism. Cell 137:216-33
11. Searfoss GH, Jordan WH, Calligaro DO, et al. 2003. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J. Biol. Chem. 278:46107-16
12. Wong GT, Manfra D, Poulet FM, et al. 2004. Chronic treatment with the gamma-secretase inhibitor LY-411, 575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279:12876-82
13. Doody RS, Raman R, Farlow M, et al. 2013. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369:341-50
14. Coric V, van Dyck CH, Salloway S, et al. 2012. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch. Neurol. 69:1430-40
15. Wolfe MS. 2007. gamma-Secretase modulators. Curr. Alzheimer Res. 4:571-73
16. Teranishi Y, Inoue M, Yamamoto NG, et al. 2015. Proton myo-inositol cotransporter is a novel gammasecretase associated protein that regulates A production without affecting Notch cleavage. FEBS J. 282:3438-51
17. Frykman S, Teranishi Y, Hur J-YY, et al. 2012. Identification of two novel synaptic-secretase associated proteins that affect amyloid-peptide levels without alteringNotch processing. Neurochem. Int. 61:108-18
18. Teranishi Y, Hur J-YY, Gu GJ, et al. 2012. Erlin-2 is associated with active-secretase in brain and affects amyloid-peptide production. Biochem. Biophys. Res.commun. 424:476-81
19. Kandalepas PC, Sadleir KR, Eimer WA, et al. 2013. The Alzheimer's beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 126:329-52
20. Ghosh AK, Gemma S, Tang J. 2008. beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 5:399-408
21. Yan R, Vassar R. 2014. Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 13:319-29
22. Atwal JK, Chen Y, Chiu C, et al. 2011. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci. Transl. Med. 3:84ra43
23. Arbel M, Yacoby I, Solomon B. 2005. Inhibition of amyloid precursor protein processing by betasecretase through site-directed antibodies. PNAS 102:7718-23
24. Mawuenyega KG, Sigurdson W, Ovod V, et al. 2010. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330:1774
25. Selkoe DJ. 2001. Clearing the brain's amyloid cobwebs. Neuron 32:177-80
26. SaidoT, LeissringMA. 2012. Proteolytic degradation of amyloid beta-protein. Cold Spring Harb. Perspect. Med. 2:a006379
27. Saito T, Iwata N, Tsubuki S, et al. 2005. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. Med. 11:434-39
28. Jacobsen JS, Comery TA, Martone RL, et al. 2008. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. PNAS 105:8754-59
29. Mueller-Steiner S, Zhou Y, Arai H, et al. 2006. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51:703-14
30. Sun B, Zhou Y, Halabisky B, et al. 2008. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 60:247-57
31. Schenk D, Barbour R, Dunn W, et al. 1999. Immunization with amyloid-beta attenuates Alzheimerdisease-like pathology in the PDAPP mouse. Nature 400:173-77
32. Morgan D, Diamond DM, Gottschall PE, et al. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-85
33. Holmes C, BocheD, WilkinsonD, et al. 2008. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-23
34. Solomon B, Koppel R, Hanan E, et al. 1996. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. PNAS 93:452-55
35. Legleiter J, Czilli DL, Gitter B, et al. 2004. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J. Mol. Biol. 335:997-1006
36. Solomon B, Koppel R, Frankel D, et al. 1997. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. PNAS 94:4109-12
37. FrenkelD, KatzO, Solomon B. 2000. Immunization against Alzheimer's beta-amyloid plaques viaEFRH phage administration. PNAS 97:11455-59
38. Moreth J, Mavoungou C, Schindowski K. 2013. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets Immun. Ageing 10:18
39. Bohrmann B, BaumannK, Benz J, et al. 2012. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheimers Dis. 28:49-69
40. HaassC, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8:101-12
41. Englund H, Sehlin D, Johansson AS, et al. 2007. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J. Neurochem. 103:334-45
42. Sevigny J, Chiao P, BussièreT, et al. 2016. The antibody aducanumab reduces Aplaques in Alzheimer's disease. Nature 537:50-56
43. Hartl FU, Hayer-Hartl M. 2002. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295:1852-58
44. Arosio P, Michaels TC, Linse S, et al. 2016. Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat.commun. 7:10948
45. Gupta R, Kapoor N, Raleigh DP, et al. 2012. Nucleobindin 1 caps human islet amyloid polypeptide protofibrils to prevent amyloid fibril formation. J. Mol. Biol. 421:378-89
46. Xu LQ, Wu S, Buell AK, et al. 2013. Influence of specific HSP70 domains on fibril formation of the yeast prion protein Ure2. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368:20110410
47. Muchowski PJ. 2002. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones Neuron 35:9-12
48. Knowles TP, Vendruscolo M, Dobson CM. 2014. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell. Biol. 15:384-96
49. Cohen SI, Vendruscolo M, Dobson CM, et al. 2012. From macroscopic measurements to microscopic mechanisms of protein aggregation. J. Mol. Biol. 421:160-71
50. Miura K, Titani K, Kurosawa Y, et al. 1992. Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure. Biochem. Biophys. Res.commun. 187:375-80
51. Lin P, Li F, Zhang YW, et al. 2007. Calnuc binds to Alzheimer's beta-amyloid precursor protein and affects its biogenesis. J. Neurochem. 100:1505-14
52. Wang Y, Mandelkow E. 2016. Tau in physiology and pathology. Nat. Rev. Neurosci. 17:5-21
53. Caillet-Boudin M-LL, Bueé L, Sergeant N, et al. 2015. Regulation of human MAPT gene expression. Mol. Neurodegeneration 10:28
54. Ke YD, Suchowerska AK, van der Hoven J, et al. 2012. Lessons from tau-deficient mice. Int. J. Alzheimer's Dis. 2012:87327
55. Roberson ED, Scearce-Levie K, Palop JJ, et al. 2007. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316:750-54
56. Leroy K, Ando K, Laporte V, et al. 2012. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am. J. Pathol. 181:1928-40
57. DeVos SL, Goncharoff DK, ChenG, et al. 2013. Antisense reduction of tau in adultmice protects against seizures. J. Neurosci. 33:12887-97
58. Santa-Maria I, Alaniz ME, Renwick N, et al. 2015. Dysregulation ofmicroRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J. Clin. Investig. 125:681-86
59. Barten DM, Fanara P, Andorfer C, et al. 2012. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J. Neurosci. 32:7137-45
60. Zhang B, Carroll J, Trojanowski JQ, et al. 2012. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32:3601-11
61. Jeganathan S, vonBergenM, Brutlach H, et al. 2006. Global hairpin folding of tau in solution. Biochemistry 45:2283-93
62. Wischik CM, NovakM, Thøgersen HC, et al. 1988. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. PNAS 85:4506-10
63. Wegmann S, Medalsy ID, Mandelkow E, et al. 2013. The fuzzy coat of pathological human Tau fibrils is a two-layered polyelectrolyte brush. PNAS 110:21:E313-E321
64. von Bergen M, Friedhoff P, Biernat J, et al. 2000. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. PNAS 97:5129-34
65. Peeraer E, Bottelbergs A, Van Kolen K, et al. 2015. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol. Dis. 73:83-95
66. Clavaguera F, Hench J, Lavenir I, et al. 2014. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 127:299-301
67. Sanders DW, Kaufman SK, DeVos SL, et al. 2014. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82:1271-88
68. HochgräfeK, Sydow A, MateniaD, et al. 2015. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol.commun. 3:25
69. Baddeley TC, McCaffrey J, Storey JM, et al. 2015.complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. J. Pharmacol. Exp. Ther. 352:110-18
70. Theunis C, Crespo-Biel N, Gafner V, et al. 2013. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy. PLOS ONE 8:e72301
71. Kontsekova E, Zilka N, Kovacech B, et al. 2014. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res. Ther. 6:44
72. Pedersen JT, Sigurdsson EM. 2015. Tau immunotherapy for Alzheimer's disease. Trends Mol. Med. 21:394-402
73. Hanisch UK, Kettenmann H. 2007. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10:1387-94
74. Franceschi C, Bonafe M, Valensin S, et al. 2000. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 908:244-54
75. Streit WJ, Sammons NW, Kuhns AJ, et al. 2004. Dystrophic microglia in the aging human brain. Glia 45:208-12
76. Wes PD, Holtman IR, BoddekeEW, et al. 2016. Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease. Glia 64:197-213
77. Orre M, Kamphuis W, Osborn LM, et al. 2014. Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice. Neurobiol. Aging 35:1-14
78. Ulland TK, Wang Y, Colonna M. 2015. Regulation of microglial survival and proliferation in health and diseases. Semin. Immunol. 27:410-15
79. Ransohoff RM. 2009. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 31:711-21
80. Aisen PS, Gauthier S, Vellas B, et al. 2007. Alzhemed: a potential treatment for Alzheimer's disease. Curr. Alzheimer Res. 4:473-78
81. Yan SD, Chen X, Fu J, et al. 1996. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-91
82. Lue LFF, Yan SD, Stern DM, et al. 2005. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 4:249-66
83. Ǵ omez-Nicola D, FransenNL, Suzzi S, et al. 2013. Regulation ofmicroglial proliferation during chronic neurodegeneration. J. Neurosci. 33:2481-93
84. Gomez-Nicola D, Perry VH. 2015. Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity. Neuroscientist 21:169-84
85. Li T, Pang S, Yu Y, et al. 2013. Proliferation of parenchymal microglia is themain source of microgliosis after ischaemic stroke. Brain J. Neurol. 136:3578-88
86. Miguel-Alvarez M, Santos-Lozano A, Sanchis-Gomar F, et al. 2015. Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect. Drugs Aging 32:139-47
87. Torrent M, Pulido D, Nogués MV, et al. 2012. Exploring new biological functions of amyloids: bacteria cell agglutination mediated by host protein aggregation. PLOS Pathog. 8(11):e1003005
88. Kagan BL. 2011. Antimicrobial amyloids Biophys. J. 100:1597-98
89. Kagan BL, Jang H, Capone R, et al. 2012. Antimicrobial properties of amyloid peptide. Mol. Pharm. 9:708-17
90. Kumar DKV, Choi SH, Washicosky KJ, et al. 2016. Amyloid-peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. Sci. Transl. Med. 8:340ra72
91. Peila R, Rodriguez BL, Launer LJ, et al. 2002. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51:1256-62
92. Hughes TF, Borenstein AR, Schofield E, et al. 2009. Association between late-life body mass index and dementia: the Kame Project. Neurology 72:1741-46
93. Kivipelto M, Ngandu T, Fratiglioni L, et al. 2005. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 62:1556-60
94. Whitmer RA, Gunderson EP, Quesenberry CP, et al. 2007. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr. Alzheimer Res. 4:103-9
95. Martin B, Mattson MP, Maudsley S. 2006. Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res. Rev. 5:332-53
96. Scarmeas N, Luchsinger JA, Schupf N, et al. 2009. Physical activity, diet, and risk of Alzheimer disease. JAMA 302:627-37
97. Frolich L, Blum-Degen D, Bernstein HG, et al. 1998. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J. Neural Trans. 105:423-38
98. QiuWQ, Folstein MF. 2006. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 27:190-98
99. Heneka MT, SastreM, Dumitrescu-Ozimek L, et al. 2005. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain J. Neurol. 128:1442-53
100. Pedersen WA, McMillan PJ, Kulstad JJ, et al. 2006. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199:265-73
101. Risner ME, Saunders AM, Altman JF, et al. 2006. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenom. J. 6:246-54
102. Jack CR Jr., Bennett DA, Blennow K, et al. 2016. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87:539-47